scholarly journals PANCREATODUODENECTOMY FOR RETROPANCREATIC HEAD LYMPH NODE INVOLVEMENT FROM LIVER METASTASIS OF COLON CANCER-REPORT OF A CASE-

2000 ◽  
Vol 61 (7) ◽  
pp. 1857-1861
Author(s):  
Yasuhiko NAGANO ◽  
Kaoru NAGAHORI ◽  
Kuniya TANAKA ◽  
Hideyuki IKE ◽  
Shinji TOGO ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Lymph Node ◽  
Liver Metastasis ◽  
Lymph Node Involvement ◽  
Node Involvement

Evaluating the prognostic significance of lymphovascular invasion in stage II and III colon cancer.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 685-685 ◽  
Author(s):  
Dorotea Mutabdzic ◽  
Shalana BL O'Brien ◽  
Elizabeth A. Handorf ◽  
Karthik Devarajan ◽  
Sanjay S. Reddy ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Overall Survival ◽  
Lymph Node ◽  
High Risk ◽  
Adjuvant Chemotherapy ◽  
Lymphovascular Invasion ◽  
Lymph Node Involvement ◽  
Stage Ii ◽  
Stage Iii ◽  
Node Involvement

685 Background: Presence of lymphovascular invasion (LVI) is known to be a predictor of lymph node involvement in colon adenocarcinoma (CA). Lymph node involvement is associated with poorer prognosis necessitating adjuvant therapy. While some studies have suggested that LVI is a predictor of worse overall survival in early stage colon cancer, the significance of LVI on prognosis has not been tested in a comprehensive North American data set. Methods: Patients with stage II and III CA with LVI data available and those who received predefined standard of care treatment were identified from the National Cancer Data Base (NCDB) from 2011 to 2015. The relationship between LVI and overall survival was tested using Kaplan-Meier survival curves and Cox proportional hazards regression analysis after adjusting for relevant clinical and demographic variables. Hazard ratios and 95% confidence intervals are reported along with median overall survival (OS) where available. Results: The dataset included 93,070 patients with stage II and 66,701 patients with stage III CA. The proportion of patients with LVI was 13% in stage II and 47% in stage III CA. After adjusting for age, sex, gender, race, comorbidities, socioeconomic status, T, and N stage, LVI was associated with worse OS in stage II, HR 1.2 (1.15-1.25, p < 0.001), and in stage III, HR 1.25 (1.21-1.30, p < 0.001), CA. Median OS was 6.51 years with LVI versus. 6.85 years without LVI in stage II compared with 6.57 years with LVI versus not reached without LVI in stage III CA. Of the stage II patients with LVI, 20% received adjuvant chemotherapy (CT) and median OS was 6.91 years for those who did versus 6.07 years for those who did not receive CT. Conclusions: Our data suggest that LVI is an important predictor of OS in stage II and III CA. There is evidence that adjuvant chemotherapy improves OS in advanced CA but there remains uncertainty as to the benefit in stage II. Despite this uncertainty, guidelines suggest consideration of adjuvant CT in patients with high-risk stage II disease. Our data support the recommendation that LVI be considered a high-risk feature in stage II disease. Further studies are necessary to examine whether the type or duration of CT should differ for patients with CA and LVI.

Stroma-High Lymph Node Involvement Predicts Poor Survival More Accurately for Patients with Stage III Colon Cancer

2016 ◽  
Vol 01 (02) ◽  
Author(s):  
Gabi W van Pelt ◽  
Torben F Hansen ◽  
Esther Bastiaannet ◽  
Sanne Kjær Frifeldt ◽  
J Han JM van Krieken ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Lymph Node ◽  
Lymph Node Involvement ◽  
Stage Iii ◽  
Poor Survival ◽  
Stage Iii Colon Cancer ◽  
Node Involvement ◽  
High Lymph Node

scholarly journals Association Between Chemotherapy and Survival in T1 Colon Cancer With Lymph Node Metastasis: A Propensity-Score Matched Analysis

2021 ◽  
Vol 11 ◽  
Author(s):  
Wangxin Yan ◽  
Huizhen Zhou ◽  
Si Shi ◽  
Jixu Lin ◽  
Qiangkang Lin
Keyword(s):  
Colon Cancer ◽  
Lymph Node ◽  
Propensity Score ◽  
Lymph Nodes ◽  
Tumor Grade ◽  
Female Gender ◽  
Lymph Node Involvement ◽  
Black Race ◽  
Node Involvement ◽  
Cancer Specific Mortality

This study aimed to comprehensively examine the efficacy of chemotherapy in T1 colon cancer patients with lymph node metastasis.MethodsThe differences in categorical variables in colon cancer patients according to lymph node status were evaluated by Pearson’s chi-square test. The Kaplan-Meier method was used to assess Cancer-specific survival (CSS) and overall survival (OS) with the log-rank test. Cox proportional hazards models were built, multivariate Cox regression analyses were performed with the hazard ratio (HR) and 95% confidence interval (CI) to identify the potential independent prognostic factors. Propensity score matching was also undertaken to adjust for treatment bias due to measured confounders.ResultsYounger age (52.2% VS. 43.0% for ≤ 65 years old, p &lt; 0.001), female gender (50.3% VS. 46.8% for female, p &lt; 0.001), more lymph nodes harvested (68.1% VS. 46.6% for ≥12 lymph nodes harvested, p &lt; 0.001), Black race (13.6% VS. 12.0% for the Black race, p &lt; 0.001), and higher tumor grade (14.2% VS. 5.6% for grade III/IV, p &lt; 0.001) were more prone to be diagnosed with lymph node involvement. The receipt of adjuvant chemotherapy following radical surgery significantly reduced the risk of colon cancer-specific mortality by 33.9% after propensity-score matching (HR = 0.661, 95%CI = 0.476-0.917, p = 0.013).ConclusionsYounger age, female gender, more lymph nodes harvested, Black race, and higher tumor grade were more prone to be diagnosed with lymph node involvement. The receipt of adjuvant chemotherapy following radical surgery also significantly decreased the risk of colon cancer-specific mortality by 33.9% in T1 colon cancer with lymph node involvement.

scholarly journals Tumor-Stroma Lymph Node Involvement is a Heterogeneous Process and Adds to Prognosis for Stage III Colon Cancer Patients

2013 ◽  
Vol 24 ◽  
pp. iv96
Author(s):  
Gabi Van Pelt ◽  
Vincent Smit ◽  
Hans Gelderblom ◽  
Han Van Krieken ◽  
Rob Tollenaar ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Tumor Stroma ◽  
Lymph Node Involvement ◽  
Stage Iii ◽  
Heterogeneous Process ◽  
Stage Iii Colon Cancer ◽  
Node Involvement

scholarly journals The clinical significance of preoperative plasma fibrinogen levels and platelet counts in resectable colon cancer

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Berrin Papila Kundaktepe ◽  
Cigdem Papila
Keyword(s):  
Colon Cancer ◽  
Lymph Node ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Fibrinogen Level ◽  
Venous Invasion ◽  
Positive Association ◽  
Lymph Node Involvement ◽  
Plasma Fibrinogen ◽  
Node Involvement

Abstract Background and aim Several aspects of the correlation between colon cancer and hemostatic markers are still unknown to many researchers in the field. In this study, we evaluated the association, if any, of preoperative platelet (PLT) counts and plasma fibrinogen levels with postoperative lymph node involvement and venous invasion in colon cancer patients. Methods This study retrospectively included eighty patients with colon cancer (mean age 58.09 years; 37% female 63% male). Results Patients with negative lymph nodes and venous invasion showed a significantly lower PLT count and higher fibrinogen level than their counterparts, i.e., patients with positive lymph nodes (p<0.001, all of them) and venous invasion (p<0.001, all of them). The results also showed a positive association of PLT counts and fibrinogen levels with lymphatic invasion (r=0.670, p<0.001 and r=0.639, p<0.001, respectively) and a positive association of PLT counts and fibrinogen levels with venous invasion (r=0.3988, p<0.001 and r=0.5268, p<0.001, respectively). According to the results of the ROC curve analysis, when the PLT count cutoff was 290/mm3, the sensitivity and specificity were 82% and 86.67%, respectively (AUC = 0.8840, p<0.0001, 95% CI 0.8084–0.9596). When the fibrinogen level cutoff was 310.0 mg/dL, the sensitivity and specificity were 72% and 96.67%, respectively (AUC 0.8790, p <0.0001, 95% CI 0.8067–0.9513). Conclusion The preoperative PLT count and plasma fibrinogen level may be considered key markers to monitor postoperative lymph node involvement and venous invasion in colon cancer patients.

scholarly journals Hepatic Lymph Node Involvement in Patients with Synchronous Liver Metastasis of Colorectal Cancer

2007 ◽  
Vol 60 (7) ◽  
pp. 392-397
Author(s):  
K. Ishibashi ◽  
T. Ishiguro ◽  
J. Sobajima ◽  
T. Sakimoto ◽  
T. Ohsawa ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Lymph Node ◽  
Liver Metastasis ◽  
Lymph Node Involvement ◽  
Synchronous Liver Metastasis ◽  
Node Involvement ◽  
Hepatic Lymph Node

scholarly journals Stratification of Stage III colon cancer may identify a patient group not requiring adjuvant chemotherapy

2020 ◽  
Author(s):  
Yasir G. Malik ◽  
Lars Gustav Lyckander ◽  
Jonas C. Lindstrøm ◽  
Olof Vinge-Holmquist ◽  
Ariba E. Sheikh ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Overall Survival ◽  
Lymph Node ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Vascular Invasion ◽  
Lymph Node Involvement ◽  
Stage Iii ◽  
Stage Iii Colon Cancer ◽  
Node Involvement

Abstract Purpose Adjuvant chemotherapy for colon cancer with lymph node involvement (Stage III) has been the standard of care since the 1990s. Meanwhile, considerable evolvement of surgery combined with dedicated histopathological examinations may have led to stage migration. Furthermore, prognostic factors other than lymph node involvement have proven to affect overall survival. Thus, adjuvant chemotherapy in Stage III colon cancer should be reconsidered. The objective was to compare recurrence rates and survival in stage III colon cancer patients treated with or without adjuvant chemotherapy. Further, to assess the impact of extensive mesenterectomy, lymph node stage and vascular invasion on outcome. Methods Consecutive patients operated for Stage III colon carcinoma between 31 December 2005 and 31 December 2015 were identified in the pathological code register by matching colon (T67) and either adenocarcinoma (M81403) or mucinous adenocarcinoma (M84803), with lymph node (T08) and metastasis of adenocarcinoma (M81406 or M84806). Medical records of all identified patients were reviewed. Results Of 216 identified patients, 69 received no postoperative adjuvant chemotherapy (group NC), 69 insufficient adjuvant chemotherapy (FLV or < minimum recommended 6 cycles FLOX, group IC), and 78 sufficient adjuvant chemotherapy (≥ 6 cycles FLOX, group SC). When adjusted for age and comorbidity, 5-year overall survival did not differ statistically significant between groups (76% vs. 83% vs. 85%, respectively). Vascular invasion and a high lymph node ratio significantly reduced overall survival. Conclusion The findings imply that subgroups of Stage III colon cancer patients have good prognosis also without adjuvant chemotherapy. For definite conclusions about necessity of adjuvant chemotherapy, prospective trials are needed.

Sign in / Sign up

Export Citation Format

Share Document